CB-13 (CRA13, SAB-378) is a
cannabinoid
Cannabinoids () are several structural classes of compounds found in the cannabis plant primarily and most animal organisms (although insects lack such receptors) or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tet ...
drug, which acts as a potent
agonist
An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ag ...
at both the
CB1 and
CB2 receptors, but has poor
blood–brain barrier
The blood–brain barrier (BBB) is a highly selective semipermeable border of endothelial cells that prevents solutes in the circulating blood from ''non-selectively'' crossing into the extracellular fluid of the central nervous system where ne ...
penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as
catalepsy
Catalepsy (from Ancient Greek , , "seizing, grasping") is a nervous condition characterized by muscular rigidity and fixity of posture regardless of external stimuli, as well as decreased sensitivity to pain.
Signs and symptoms
Symptoms in ...
only appearing at much higher dose ranges. It has
antihyperalgesic properties in animal studies, and has progressed to preliminary human trials.
Legal Status
As of October 2015 CB-13 is a controlled substance in China.
See also
*
AM-6545
AM-6545 is a drug which acts as a peripherally selective silent antagonist for the CB1 receptor, and was developed for the treatment of obesity. Other cannabinoid antagonists such as rimonabant have been marketed for this application, but have ...
*
AZ-11713908
References
Cannabinoids
Designer drugs
Naphthalenes
Aromatic ketones
Naphthol ethers
Peripherally selective drugs
Ethers
{{cannabinoid-stub